|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122379 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-13 15:04:11 |
|
注册时间: Date of Registration: |
2026-04-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
减重药物的临床综合评价 |
|
Public title: |
Clinical Comprehensive Evaluation on Weight-loss Drugs |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
减重药物的临床综合评价 |
|
Scientific title: |
Clinical Comprehensive Evaluation on Weight-loss Drugs |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
于恒彩 |
研究负责人: |
高田田 |
|
Applicant: |
Hengcai Yu |
Study leader: |
Tiantian Gao |
|
申请注册联系人电话: Applicant telephone: |
+86 188 1084 7169 |
研究负责人电话:
Study leader's |
+86 137 9104 6612 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yuhengcai200712761@163.com |
研究负责人电子邮件: Study leader's E-mail: |
ttsky313@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市经五纬七路324号 |
研究负责人通讯地址: |
山东省济南市经五纬七路324号 |
|
Applicant address: |
No. 324, Jingwu and Wei7 Road, Jinan City, Shandong Province |
Study leader's address: |
No. 324, Jingwu and Wei7 Road, Jinan City, Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东省立医院 |
||
|
Applicant's institution: |
Shangong Provincial Hospital |
||
|
研究负责人所在单位: |
山东省立医院 |
||
|
Affiliation of the Leader: |
Shangong Provincial Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
省医伦批第(SWYX:NO. 2025-1081) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东省立医院涉及人的生物医学伦理委员会 |
||
|
Name of the ethic committee: |
The Human Biomedical Ethics Committee of Shandong Provincial Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-27 00:00:00 | ||
|
伦理委员会联系人: |
杨爱辉 |
||
|
Contact Name of the ethic committee: |
Yang Aihui |
||
|
伦理委员会联系地址: |
山东省济南市经五纬七路324号 |
||
|
Contact Address of the ethic committee: |
No. 324, Jingwu and Wei7 Road, Jinan City, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 6877 6025 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东省立医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shandong Provincial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
济南市经五路324号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 324, Jingwu and Wei7 Road, Jinan City, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
江苏众煦医药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Jiangsu Zhongxu Pharmaceutical Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
肥胖或超重且不合并糖尿病 |
||||||||||||||||||||||
|
Target disease: |
overweight or obesity |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究将开展减重药物的临床综合评价,在安全性、有效性、经济性、创新性、适宜性和可及性等多个维度形成减重药物的临床综合评价研究报告,旨在为药物治疗提供高质量的循证证据,为医疗保健提供者和政策制定者提供关于超重或肥胖个体最有效的药物治疗方案,不仅有助于个性化体重管理,而且有可能降低死亡率和医疗保健成本,最终改善人类健康状况。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study will conduct a comprehensive clinical evaluation of weight loss drugs, forming a comprehensive clinical evaluation research report on weight loss drugs from multiple dimensions including safety, efficacy, cost-effectiveness, innovation, suitability, and accessibility. The aim is to provide high-quality evidence-based support for drug therapy and offer healthcare providers and policymakers the most effective drug treatment options for individuals who are overweight or obese. This not only helps in personalized weight management but also has the potential to reduce mortality and healthcare costs, ultimately improving human health. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄≥18岁;和肥胖(BMI ≥28 kg·m-2)或超重(BMI ≥24.0~27. 9 kg·m-2)并且至少有一种体重相关并发症(如糖尿病前期、高血压、血脂异常、阻塞性睡眠呼吸暂停、心血管疾病、代谢相关脂肪性肝病、或负重关节痛);和有一次或多次节食减重失败的经历。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age ≥ 18 years; 2.Obesity (BMI ≥ 28 kg·m-2) or overweight (BMI ≥ 24.0 - 27.9 kg·m-2) and having at least one weight-related complication (such as prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, metabolic associated fatty liver disease, or weight-bearing joint pain); 3.Having a history of one or more failed attempts at weight loss through dieting. |
||||||||||||||||||||||
|
排除标准: |
糖尿病,或入组前90天内体重变化超过5公斤(或5%),或入组前90天内使用促进体重减轻的药物治疗,或妊娠期或哺乳期妇女。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Diabetes, 2.A weight change of more than 5 kilograms (or 5%) within 90 days before enrollment, 3.Treatment with weight loss-promoting drugs within 90 days before enrollment, 4.Women who are pregnant or lactating. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-01 00:00:00至 To 2028-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2028-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表方式 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |